

TALKING WITH YOUR PATIENTS ABOUT iDose[®] TR

iDose[®] TR 
(travoprost intracameral
implant) 75 mcg

The doctor-to-patient dialogue is crucial to establishing understanding and trust. Conversations may vary and take a while to master when introducing a unique treatment option for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Here are some talking points to get the conversation started and help you introduce iDose[®] TR to appropriate patients within your practice.



Finding the Barrier:

When you enter the room with the patient, it is important to find the barrier.

Opening:

The last time you were here, we prescribed drops for you. What difficulties are you having with your drops?

Ask Additional Questions:

- How many times a week do you miss a dose?
- Did you pick up your refill?
- Do your eyes bother you?

Look for leading indicators. Document the difficulties in the patient chart (eg, forgetfulness, administration, side effects, uncontrolled). The key is to address the problem with a solution that meets the patient's needs.



Offer a Solution:

There is an FDA-approved treatment called iDose TR that will help reduce eye pressure for your glaucoma.¹ It utilizes the same medication that's been used for decades, but rather than requiring you to apply the medication to your eyes daily, iDose TR allows me to place the medication directly inside your eye where it's most needed.² By doing so, this treatment is designed to give you a longer duration of therapy than your existing prescription drops today. This treatment could help reduce some of the challenges or side effects you've mentioned are burdensome.^{3,4}



iDose TR Patient-Friendly Procedure Description:

iDose TR has been shown to be an effective and safe treatment that can help reduce your eye pressure.⁴ I will gently place the treatment inside your eye in a clean and sterile environment.² You will be able to go home after the minor procedure and return to normal activities within 48 hours.⁵ It's normal after the procedure for your eye to be red, irritated, and have minor discomfort, but if it persists, please give me a call.²



Strong Recommendation:

If someone in my family or I had high eye pressure associated with glaucoma, the treatment that I would recommend—and want for myself—would be iDose TR. I do believe this is the best option for you.

WHAT PATIENTS MAY ASK

RESPONSE CONSIDERATIONS

Will the treatment hurt or will I feel the procedure?

No, your eye will be gently sedated. You should not feel anything during the procedure.³

Is iDose TR safe?

iDose TR is shown to be safe and effective. The risk of infection is very low.²

Is iDose TR covered by insurance?

We will check your benefits and confirm you have all the necessary information to proceed. There are also programs to assist, if needed.

How long will the treatment last?

This treatment is designed to give you a longer duration of therapy than your existing prescription drops today.^{1,3,4}

- 8/10 patients were free of prescription drops at 12 months⁴
- Designed to deliver medication for up to three years⁴

Additional Considerations:

- 1 Confidence** is KEY
- 2 Avoid overwhelming patients** with too much information, keep it simple, but provide what they need to know
- 3 Use patient-friendly language** and keep it factual
- 4 Stick to three key points** so your patients remember what you want them to know

References:

1. Berdahl JP, Sarkisian SR Jr, Ang RE, et al; Travoprost Intraocular Implant Study Group. Efficacy and safety of the travoprost intraocular implant in reducing topical IOP-lowering medication burden in patients with open-angle glaucoma or ocular hypertension. *Drugs*. 2024;84(1):83-97. doi:10.1007/s40265-023-01973-7
2. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023.
3. Sarkisian SR, Ang RE, Lee AM, et al. Travoprost intracameral implant for open-angle glaucoma or ocular hypertension: 12-month results of a randomized, double-masked trial. *Ophthalmol Ther*. 2024;13(4):995-1014. doi:10.1007/s40123-024-00898-y
4. Sarkisian SR Jr, Ang RE, Lee AM, et al; GC-010 Travoprost Intraocular Implant Investigators. Phase 3 randomized clinical trial of the safety and efficacy of travoprost intraocular implant in patients with open-angle glaucoma or ocular hypertension. *Ophthalmology*. Published online February 27, 2024. doi:10.1016/j.ophtha.2024.02.022
5. Data on file, Glaukos Corporation.

INDICATIONS AND USAGE

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

IMPORTANT SAFETY INFORMATION

Dosage and Administration

For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

Contraindications

iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

Warnings and Precautions

iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

Adverse Reactions

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Please see full Prescribing Information.

You are encouraged to report all side effects to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also call Glaukos at 1-888-404-1644.

iDose[®] TR 
(travoprost intracameral
implant) 75 mcg



View full Prescribing
Information at
iDoseTRhcp.com

GLAUKOS 